In a recently released analyst research report, Oppenheimer & Co. analyst, Rupesh Parikh, reiterated their Perform rating on shares of international cannabis giant Tilray Inc. (NASDAQ:TLRY) citing industry pressures despite long-term positives for the company.
According to Barron’s, “Parikh writes that he’s upbeat about Tilray’s ability to capitalize on what he sees has three key markets—global adult use, global medical use, and global hemp and CBD use. He thinks the company looks especially well positioned on the medical front, and while we’re still awaiting clarity on the CBD market in the U.S., supply chain issues in Canada are easing. Moreover, he says that Tilray’s goal of achieving positive earnings before interest, taxes, depreciation, and amortization by the end of 2020 is still possible.”
Most recently, TruTrace Technologies Inc. (CSE:TTT) (OTC:TTTSF) announced that Tilray Canada Ltd., a subsidiary of Tilray, Inc., joined the Shoppers Drug Mart medical cannabis verification pilot program that it implements.
Be sure to subscribe to updates here so you never miss an important development.
Get Real-Time Updates from MJobserver.com